RecruitingBiological intervention4D-150 in Patients With Neovascular (Wet) Age-Related Macular DegenerationPhase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.